BsAbs before CD19 CAR-T: full speed ahead! No … ← Armand P, Zinzani PL, Lee HJ, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023;142(10):878-886 BsAbs before CD19 CAR-T: full speed ahead! →